RT Journal Article
SR Electronic
T1 Genome-wide association meta-analysis identifies novel ancestry-specific primary open-angle glaucoma loci and shared biology with vascular mechanisms and cell proliferation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.16.21267891
DO 10.1101/2021.12.16.21267891
A1 Lo Faro, Valeria
A1 Bhattacharya, Arjun
A1 Zhou, Wei
A1 Zhou, Dan
A1 Wang, Ying
A1 Läll, Kristi
A1 Kanai, Masahiro
A1 Lopera-Maya, Esteban
A1 Straub, Peter
A1 Pawar, Priyanka
A1 Tao, Ran
A1 Zhong, Xue
A1 Namba, Shinichi
A1 ,
A1 Sanna, Serena
A1 Nolte, Ilja M.
A1 Okada, Yukinori
A1 Ingold, Nathan
A1 MacGregor, Stuart
A1 Snieder, Harold
A1 Surakka, Ida
A1 Willer, Cristen
A1 Martin, Alicia R.
A1 Brantley, Milam A.
A1 Gamazon, Eric R.
A1 Jansonius, Nomdo M.
A1 Joos, Karen
A1 Cox, Nancy J.
A1 Hirbo, Jibril
YR 2021
UL http://medrxiv.org/content/early/2021/12/26/2021.12.16.21267891.abstract
AB Primary open-angle glaucoma (POAG) is a complex eye disease characterized by progressive loss of optic nerve function that, if untreated, ultimately leads to irreversible blindness. To date, the biological mechanisms causing POAG are still unclear. There is disparity in POAG prevalence, clinical presentations and outcomes across ancestries. Here, we aim to identify unique genetics that underlie risk to POAG and evaluate the potential connection with vascular mechanisms. We performed POAG meta-analysis across 15 biobanks that are part of the Global Biobank Meta-analysis Initiative, with two previously published multi-ancestry analyses for a total of 1,478,037 individuals from six ancestries (46,325 cases and 1,431,712 controls). A total of 109 genome-wide significantly associated loci (p<5e-8) were identified, 18 of which were novel. Three of these novel loci are ancestry-specific, two African-specific and the third specific to northern Europeans. We also identified five sex-specific novel loci, four of which are African-specific and one European-specific. To explore biological implications underlying these variant-trait associations, we performed gene enrichment analysis, gene prioritization analysis and transcriptome-wide association studies (TWAS) implicating genes related to vascular-related functions, blood vessels, angiogenesis, and cancer. A fifth of TWAS-prioritized genes with vascular-related and/or cell senescence/proliferation functional roles or have been implicated in vascular or neoplastic diseases are primary ciliary related genes. We further performed extensive statistical validation analysis of genes in the SIX6 and well-known CDKN2B-AS1 loci, previously implicated in POAG, cardiovascular diseases, and cancers across multiple ancestries. We found evidence of significant interaction between SIX6 rs33912345 and causal variants in chr9p21.3, with concomitant effect on expression of a primary cilia gene CDKN2A and CDKN2B at the CDKN2B-AS1 locus. Phenome-wide association analysis of POAG genetic risk burden across five biobanks and genetic correlation analysis also show the shared biology between POAG and vascular and neoplastic traits. In summary, our findings suggest that some POAG risk variants may be ancestry-specific, sex-specific, or both. Our findings further support the contribution of vascular and proliferation genes in POAG and suggest potential involvement of primary cilia in POAG pathogenesis.Competing Interest StatementThe spouse of Cristen Willer works at Regeneron Pharmaceuticals. Eric R. Gamazon receives an honorarium from the journal Circulation Research of the American Heart Association as a member of the Editorial Board.Funding StatementValeria Lo Faro was supported by the European Union Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No.675033 (EGRET plus). Additional funding was provided by the Rotterdamse Stichting Blindenbelangen (grant ID B20150036). Eric R. Gamazon is supported by the National Institutes of Health (NIH) Awards R35HG010718, R01HG011138, R01GM140287, and NIH/NIA AG068026. Karen Joos was supported by the Joseph Ellis Family and William Black Research Funds, and an Unrestricted Departmental Grant to the Vanderbilt Eye Institute from Research to Prevent Blindness, Inc., NY.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors